Jasper Therapeutics Completes IgAN Cohort Enrollment
The company completed enrollment in the IgA nephropathy cohort of its Phase 2 vensobafusp alfa basket study and expects initial data by year-end 2026.
The company completed enrollment in the IgA nephropathy cohort of its Phase 2 vensobafusp alfa basket study and expects initial data by year-end 2026.